Thread: Science Science is Cool....
View Single Post
Old 03-21-2017, 07:07 PM   #2698
Fish Fish is offline
Ain't no relax!
 
Fish's Avatar
 

Join Date: Sep 2005
Casino cash: $2558919
Regarding EBC-46.... it's another potential PKC treatment. Protein Kinase C. It's not really so much a treatment as a potential attack target for treating cancer and an entire host of other ailments. It's actually been around for quite some time. But you won't find many recent EBC-46 success stories or anything. It's still completely unproven. Other PKC treatments have shown to be effective, but exhibiting fatal side-effects in humans.

Quote:
https://www.ncbi..nih.gov/pmc/articles/PMC3756376/

Protein kinase C (PKC) has been a tantalizing target for drug discovery ever since it was first identified as the receptor for the tumor promoter phorbol ester in 1982. Although initial therapeutic efforts focused on cancer, additional diseases, including diabetic complications, heart failure, myocardial infarction, pain and bipolar disease were targeted as researchers developed a better understanding of the roles that PKC’s eight conventional and novel isozymes play in health and disease. Unfortunately, both academic and pharmaceutical efforts have yet to result in the approval of a single new drug that specifically targets PKC. Why does PKC remain an elusive drug target? This review will provide a short account of some of the efforts, challenges and opportunities in developing PKC modulators to address unmet clinical needs.
Quote:
http://sitn.hms.harvard.edu/flash/20...ong-way-to-go/

A recent article published in Medical Express last week touts the impressive findings of a pre-clinical study on the experimental drug EBC-46 (pictured above). In the article, they claim that EBC-46 is able to effectively destroy tumors by destroying the blood vessels that supply it with oxygen and nutrients. It is important, however, to remember that the work they are reporting on is very preliminary and has yet to be shown to be safe or effective in humans. Many promising candidate drugs fail very early on in clinical trials because of an unforeseen side-effect or because the drug simply does not work as well in humans as in animal models.

Furthermore, EBC-46 may be a novel drug, but its target is nothing new. EBC-46 targets a protein called Protein Kinase C (PKC) that, when inhibited, prevents tumor cells from making proteins that help them live. PKC has been targeted by several compounds, with one, PMA getting a phase I clinical trial (safety and efficacy in a limited group of people with cancer). Unfortunately, PMA caused severe and life-threatening side effects and the trial was stopped.

Given the questionable history of PKC inhibitors, it has yet to be seen if EBC-46 will be safe to use in humans.
__________________
Posts: 47,349
Fish is obviously part of the inner Circle.Fish is obviously part of the inner Circle.Fish is obviously part of the inner Circle.Fish is obviously part of the inner Circle.Fish is obviously part of the inner Circle.Fish is obviously part of the inner Circle.Fish is obviously part of the inner Circle.Fish is obviously part of the inner Circle.Fish is obviously part of the inner Circle.Fish is obviously part of the inner Circle.Fish is obviously part of the inner Circle.
    Reply With Quote